$NNOX

Suesskind Dan S purchased $45K of NNOX

Suesskind Dan S purchased 60,000 shares of Nano-X Imaging Ltd. (NNOX) at an average of $0.76 ($0.75–$0.76) across 2 trades on 2026-09-14.

Original reporting
SEC EDGAR · Suesskind Dan S
Published Sep 15, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 12:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NNOX
Neutral
low confidence
Mentioned
$NNOX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NNOXNeutralLow
01

Why it matters

The filing provides a transparent record of insider activity; however, the modest size limits market relevance.

02

Market read

Primary disclosure of a small insider purchase; limited trading relevance.

03

What to watch

Potential upcoming FDA filing or clinical data that may have prompted the purchase, but not disclosed.

Relevance 4/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$NNOXNeutralLow confidence
Context

Director Dan S purchased 60,000 shares for $45.3K, increasing his stake to 110,000 shares.

Expected impact

Minimal to no immediate price movement.

Evidence & confidence

Purchase amount is under $50K for a micro‑cap; market typically discounts such small trades.

Market effects

None; the transaction is company‑specific.

None; Nano‑X Imaging is a U.S. listed micro‑cap.

None

Counterpoint

The insider purchase could be a routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Nano‑X Imaging Ltd.

    Medical imaging device manufacturer listed on Nasdaq under NNOX.

  • Dan S. Suesskind

    Director of Nano‑X Imaging Ltd.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NNOXMed

Nano X Imaging Ltd (NNOX) (Q2 2026) Earnings Call Highlights: Re

Nano X Imaging Ltd (NNOX) reported a 37% year-over-year revenue increase in Q2 2026, driven by growth in teleradiology services and new partnerships. The company also announced operational streamlining and cost reductions. However, NNOX recorded a $40.7 million impairment charge, a significant decrease in cash position, and a widened net loss of $55.5 million. Management expects revenue traction in the coming months and potential market expansion due to new reimbursement codes.

$NNOXHigh

Nano-X Imaging Ltd. (NNOX): Financial results for Q2 2026

Nano-X Imaging Ltd. (NNOX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Nanox Announces Second Quarter 2026 Financial Results and Provides Business Updates Management to host conference call and webcast on Wednesday, September 9, 2026 at 8:30 AM ET PETACH TIKVA, Israel — September 9, 2026 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or

$NNOXMed

NANO-X IMAGING LTD: Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone Solution (HealthOST) in the United Kingdom

Nanox Imaging Ltd (NASDAQ: NNOX) said its subsidiary Nanox AI entered an exclusive UK sales reseller agreement with Vertec Scientific for commercialization of Nanox.AI bone solution (HealthOST). The initial three-year term requires Vertec to meet minimum annual license commitments. HealthOST is FDA-cleared and UKCA/CE-marked and was recommended by NICE in Nov 2025 for NHS use.